ProQR Therapeutics (NASDAQ:PRQR – Get Rating) has earned a consensus rating of "Hold" from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $5.80.
A number of research firms recently commented on PRQR. StockNews.com upgraded ProQR Therapeutics from a "sell" rating to a "hold" rating in a research note on Monday, May 9th. Raymond James upgraded ProQR Therapeutics from a "market perform" rating to an "outperform" rating and set a $2.00 target price for the company in a research note on Friday, August 12th. Cantor Fitzgerald downgraded ProQR Therapeutics from an "overweight" rating to a "neutral" rating in a research note on Monday, August 15th. HC Wainwright decreased their target price on ProQR Therapeutics from $4.00 to $2.00 in a research note on Monday, May 9th. Finally, Chardan Capital cut ProQR Therapeutics from a "buy" rating to a "neutral" rating in a report on Friday, August 12th.
Get ProQR Therapeutics alerts:ProQR Therapeutics Stock Up 2.2 %
NASDAQ:PRQR opened at $0.79 on Thursday. The company has a market capitalization of $56.31 million, a price-to-earnings ratio of -0.79 and a beta of 0.80. ProQR Therapeutics has a one year low of $0.53 and a one year high of $9.09. The stock has a 50-day simple moving average of $0.81 and a 200 day simple moving average of $0.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 5.93 and a current ratio of 5.93.
ProQR Therapeutics (NASDAQ:PRQR – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.04. The business had revenue of $1.09 million during the quarter, compared to the consensus estimate of $1.21 million. ProQR Therapeutics had a negative return on equity of 57.34% and a negative net margin of 1,859.05%. Sell-side analysts predict that ProQR Therapeutics will post -0.81 EPS for the current fiscal year.Institutional Investors Weigh In On ProQR Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. ProShare Advisors LLC bought a new stake in ProQR Therapeutics during the fourth quarter worth approximately $80,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of ProQR Therapeutics by 23.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 186,663 shares of the biopharmaceutical company's stock valued at $1,495,000 after buying an additional 35,261 shares in the last quarter. Alps Advisors Inc. bought a new position in shares of ProQR Therapeutics in the fourth quarter valued at $660,000. Connor Clark & Lunn Investment Management Ltd. increased its holdings in shares of ProQR Therapeutics by 82.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 69,973 shares of the biopharmaceutical company's stock valued at $560,000 after buying an additional 31,614 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its holdings in shares of ProQR Therapeutics by 14.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 3,913,394 shares of the biopharmaceutical company's stock valued at $31,346,000 after buying an additional 481,325 shares in the last quarter. Institutional investors own 31.07% of the company's stock.
ProQR Therapeutics Company Profile
(Get Rating)
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.
Read More
- Get a free copy of the StockNews.com research report on ProQR Therapeutics (PRQR)
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- Is World Wresting Entertainment Getting Ready to Be Sold?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.